EcoDrugPlus

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOJAG00000005554
Gene Symbol: BRAF
1 Cross references
218 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOJAG00000017950
Gene Symbol: BRAF
1 Cross references
218 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSOJAG00000023045
Gene Symbol: BCL2L1
1 Cross references
226 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSOJAG00000006961
Gene Symbol: BCL2L10
1 Cross references
128 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSOJAG00000017010
Gene Symbol: BCR
1 Cross references
205 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSOJAG00000019433
Gene Symbol: BTK
1 Cross references
204 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSOJAG00000006125
Gene Symbol: CCR9
1 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSOJAG00000006558
Gene Symbol: CXCR1
1 Cross references
275 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOJAG00000016798
Gene Symbol: CFTR
1 Cross references
214 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSOJAG00000002142
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSOJAG00000011020
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSOJAG00000021632
Gene Symbol: TOP1A
1 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).